Delving into the Latest Updates on TQB3915 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

TQB3915

Target

ERα

Action

antagonists

Mechanism

ERα antagonists(Estrogen receptor alpha antagonists)

Therapeutic Areas

NeoplasmsSkin and Musculoskeletal Diseases

Active Indication

Advanced Malignant Solid NeoplasmAdvanced breast cancer

Inactive Indication

Advanced cancer

Originator Organization

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Active Organization

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

1.主要目的：评估TQB3915片在晚期恶性实体瘤受试者中的安全性和耐受性；评估TQB3915片联合依维莫司在晚期乳腺癌受试者中的安全性和耐受性。 2.次要目的：评估TQB3915片在晚期恶性实体瘤受试者中的药代动力学（PK）特征；评估TQB3915片联合依维莫司在晚期乳腺癌受试者中的药代动力学（PK）特征；评估TQB3915片单药及联合依维莫司的初步抗肿瘤疗效。 3.探索性目的：探索TQB3915片治疗相关的生物标志物。

[Translation]

1. Primary purpose: To evaluate the safety and tolerability of TQB3915 tablets in subjects with advanced malignant solid tumors; To evaluate the safety and tolerability of TQB3915 tablets combined with everolimus in subjects with advanced breast cancer. 2. Secondary purpose: To evaluate the pharmacokinetic (PK) characteristics of TQB3915 tablets in subjects with advanced malignant solid tumors; To evaluate the pharmacokinetic (PK) characteristics of TQB3915 tablets combined with everolimus in subjects with advanced breast cancer; To evaluate the preliminary anti-tumor efficacy of TQB3915 tablets alone and in combination with everolimus. 3. Exploratory purpose: To explore biomarkers related to the treatment of TQB3915 tablets.

Start Date24 Jun 2022

Sponsor / Collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

NCT05416359

/ Unknown statusPhase 1

Phase I Clinical Trial of TQB3915 Tablets in Subjects With Advanced Malignant Solid Tumors

TQB3915 is a selective estrogen receptor covalent antagonist, by covalently binding to estrogen receptor, by changing the conformation of ERα, blocking intracellular signal transmission, thereby inhibiting the growth of tumor cells.

Start Date01 Jun 2022

Sponsor / Collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

100 Clinical Results associated with TQB3915

Login to view more data

100 Translational Medicine associated with TQB3915

Login to view more data

100 Patents (Medical) associated with TQB3915

Login to view more data

100 Deals associated with TQB3915

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced cancer	Phase 1	China	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	01 Jun 2022
Advanced Malignant Solid Neoplasm	Phase 1	China	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	01 Jun 2022
Advanced breast cancer	IND Approval	China	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	04 Mar 2024